Dexcom (DXCM) Cost of Revenue (2010 - 2026)

Dexcom (DXCM) has 17 years of Cost of Revenue data on file, last reported at $441.6 million in Q1 2026.

• On a quarterly basis, Cost of Revenue fell 1.21% year-over-year to $441.6 million in Q1 2026; TTM through Mar 2026 was $1.9 billion, a 10.22% increase from a year earlier, with the FY2025 full-year figure at $1.9 billion, up 16.64% from the prior year.
• Cost of Revenue for Q1 2026 stood at $441.6 million, down from $466.9 million in the prior quarter.
• Over the last five years, Cost of Revenue for DXCM reached as high as $477.9 million in Q3 2025 and fell as low as $230.7 million in Q1 2022.
• Historically, Cost of Revenue has averaged $368.0 million across 5 years, with a median of $377.6 million in 2024.
• Across the five-year window, Cost of Revenue soared 43.2% in 2022 and slipped 1.21% in 2026, its largest moves.
• Year by year, Cost of Revenue stood at $273.9 million in 2022, then soared by 37.97% to $377.9 million in 2023, then gained by 21.12% to $457.7 million in 2024, then gained by 2.01% to $466.9 million in 2025, then slipped by 5.42% to $441.6 million in 2026.
• Per Business Quant data, the three most recent Cost of Revenue figures were $441.6 million in Q1 2026, $466.9 million in Q4 2025, and $477.9 million in Q3 2025.